This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
Staff outcomes from the caring for aged dementia care resident study (CADRES): a cluster randomised trial
Jeon, Yun-Hee,
Luscombe, Georgina,
Chenoweth, Lynn,
Stein-Parbury, Jane,
Brodaty, Henry,
King, Madeleine,
Haas, Marion
Background: Dementia care mapping and person centred care are well-accepted as processes for improving care and well-being for persons with dementia living in the residential setting. However, the impact of dementia care mapping and person centred care on staff has not been well researched.; Objectives: The impact of person centred care and dementia care mapping […]
A proteomics study reveals a predominant change in MaoB expression in platelets of healthy volunteers after high protein meat diet: relationship to the methylation cycle
Zellner, Maria,
Babeluk, Rita,
Jakobsen, Lene H.,
Gerner, Christopher,
Umlauf, Ellen,
Volf, Ivo,
Roth, Erich,
Kondrup, Jens
Studies investigating the impact of high meat intake on cognition have yielded contradictory results as some show improved cognitive performance, whereas others report an increase of risk factors for dementia. However, few studies were designed to directly assess the effect of a high protein (HP) diet on both cognitive performance and corresponding biochemical parameters. A […]
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease – protocol for a controlled, randomized double-blinded trial
Egefjord, Lærke,
Gejl, Michael,
Møller, Arne,
Brændgaard, Hans,
Gottrup, Hanne,
Antropova, Olga,
Møller, Niels,
Poulsen, Henrik E.,
Gjedde, Albert,
Brock, Birgitte,
Rungby, Jørgen
Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Dockens, Randy,
Wang, Jun-Sheng,
Castaneda, Lorna,
Sverdlov, Oleksandr,
Huang, Shu-Pang,
Slemmon, Randy,
Gu, Huidong,
Wong, Oi,
Li, Hewei,
Berman, Robert M.,
Smith, Christina,
Albright, Charles F.,
Tong, Gary
Background and Objectives: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women […]
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study
Carlsson, Cynthia M.,
Xu, Guofan,
Wen, Zhifei,
Barnet, Jodi H.,
Blazel, Hanna M.,
Chappell, Richard J.,
Stein, James H.,
Asthana, Sanjay,
Sager, Mark A.,
Alsop, David C.,
Rowley, Howard A.,
Fain, Sean B.,
Johnson, Sterling C.
Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]